DNA-Binding and Transactivation Activities Are Essential for TAp63 Protein Degradation

REFERENCES

• Asher, G., J. Lotem, P. Tsvetkov, V. Reiss, L. Sachs, and Y. Shaul. 2003. p53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1. Proc. Natl. Acad. Sci. USA 100:15065–15070.
   PubMedGoogle Scholar
• Brunner, H. G., B. C. Hamel, and H. Van Bokhoven. 2002. The p63 gene in EEC and other syndromes. J. Med. Genet. 39:377–381.
   PubMed Web of Science ®Google Scholar
• Calabro, V., G. Mansueto, T. Parisi, M. Vivo, R. A. Calogero, and G. La Mantia. 2002. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J. Biol. Chem. 277:2674–2681.
   PubMed Web of Science ®Google Scholar
• Celli, J., P. Duijf, B. C. Hamel, M. Bamshad, B. Kramer, A. P. Smits, R. Newbury-Ecob, R. C. Hennekam, G. Van Buggenhout, A. van Haeringen, C. G. Woods, A. J. van Essen, R. de Waal, G. Vriend, D. A. Haber, A. Yang, F. McKeon, H. G. Brunner, and H. van Bokhoven. 1999. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 99:143–153.
   PubMed Web of Science ®Google Scholar
• Chen, J., X. Wu, J. Lin, and A. J. Levine. 1996. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16:2445–2452.
   PubMed Web of Science ®Google Scholar
• Crook, T., J. M. Nicholls, L. Brooks, J. O'Nions, and M. J. Allday. 2000. High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC). Oncogene 19:3439–3444.
   PubMedGoogle Scholar
• Dohn, M., S. Zhang, and X. Chen. 2001. p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 20:3193–3205.
   PubMed Web of Science ®Google Scholar
• Flores, E. R., K. Y. Tsai, D. Crowley, S. Sengupta, A. Yang, F. McKeon, and T. Jacks. 2002. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416:560–564.
   PubMed Web of Science ®Google Scholar
• Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296–299.
   PubMed Web of Science ®Google Scholar
• Hibi, K., B. Trink, M. Patturajan, W. H. Westra, O. L. Caballero, D. E. Hill, E. A. Ratovitski, J. Jen, and D. Sidransky. 2000. AIS is an oncogene amplified in squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 97:5462–5467.
   PubMed Web of Science ®Google Scholar
• Ho, S. N., H. D. Hunt, R. M. Horton, J. K. Pullen, and L. R. Pease. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51–59.
   PubMed Web of Science ®Google Scholar
• Kaghad, M., H. Bonnet, A. Yang, L. Creancier, J. C. Biscan, A. Valent, A. Minty, P. Chalon, J. M. Lelias, X. Dumont, P. Ferrara, F. McKeon, and D. Caput. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809–819.
   PubMed Web of Science ®Google Scholar
• Kim, S. Y., A. Herbst, K. A. Tworkowski, S. E. Salghetti, and W. P. Tansey. 2003. Skp2 regulates Myc protein stability and activity. Mol. Cell 11:1177–1188.
   PubMed Web of Science ®Google Scholar
• Koster, M. I., S. Kim, A. A. Mills, F. J. DeMayo, and D. R. Roop. 2004. p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev. 18:126–131.
   PubMed Web of Science ®Google Scholar
• Kubbutat, M. H., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387:299–303.
   PubMed Web of Science ®Google Scholar
• Kussie, P. H., S. Gorina, V. Marechal, B. Elenbaas, J. Moreau, A. J. Levine, and N. P. Pavletich. 1996. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274:948–953.
   PubMed Web of Science ®Google Scholar
• Lipford, J. R., and R. J. Deshaies. 2003. Diverse roles for ubiquitin-dependent proteolysis in transcriptional activation. Nat. Cell Biol. 5:845–850.
   PubMed Web of Science ®Google Scholar
• Little, N. A., and A. G. Jochemsen. 2001. Hdmx and Mdm2 can repress transcription activation by p53 but not by p63. Oncogene 20:4576–4580.
   PubMedGoogle Scholar
• Maisse, C., P. Guerrieri, and G. Melino. 2003. p73 and p63 protein stability: the way to regulate function. Biochem. Pharmacol. 66:1555–1561.
   PubMed Web of Science ®Google Scholar
• McKeon, F. 2004. p63 and the epithelial stem cell: more than status quo. Genes Dev. 18:465–469.
   PubMed Web of Science ®Google Scholar
• Michael, D., and M. Oren. 2002. The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev. 12:53–59.
   PubMed Web of Science ®Google Scholar
• Midgley, C. A., and D. P. Lane. 1997. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15:1179–1189.
   PubMed Web of Science ®Google Scholar
• Muratani, M., and W. P. Tansey. 2003. How the ubiquitin-proteasome system controls transcription. Nat. Rev. Mol. Cell Biol. 4:192–201.
   PubMed Web of Science ®Google Scholar
• Nylander, K., P. J. Coates, and P. A. Hall. 2000. Characterization of the expression pattern of p63 alpha and delta Np63 alpha in benign and malignant oral epithelial lesions. Int. J. Cancer 87:368–372.
   PubMed Web of Science ®Google Scholar
• Osada, M., M. Ohba, C. Kawahara, C. Ishioka, R. Kanamaru, I. Katoh, Y. Ikawa, Y. Nimura, A. Nakagawara, M. Obinata, and S. Ikawa. 1998. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med. 4:839–843.
   PubMed Web of Science ®Google Scholar
• Park, B. J., S. J. Lee, J. I. Kim, C. H. Lee, S. G. Chang, J. H. Park, and S. G. Chi. 2000. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res. 60:3370–3374.
   PubMed Web of Science ®Google Scholar
• Parsa, R., A. Yang, F. McKeon, and H. Green. 1999. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J. Investig. Dermatol. 113:1099–1105.
   PubMed Web of Science ®Google Scholar
• Reid, G., M. R. Hubner, R. Metivier, H. Brand, S. Denger, D. Manu, J. Beaudouin, J. Ellenberg, and F. Gannon. 2003. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol. Cell 11:695–707.
   PubMed Web of Science ®Google Scholar
• Salghetti, S. E., A. A. Caudy, J. G. Chenoweth, and W. P. Tansey. 2001. Regulation of transcriptional activation domain function by ubiquitin. Science 293:1651–1653.
   PubMed Web of Science ®Google Scholar
• Salghetti, S. E., M. Muratani, H. Wijnen, B. Futcher, and W. P. Tansey. 2000. Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis. Proc. Natl. Acad. Sci. USA 97:3118–3123.
   PubMed Web of Science ®Google Scholar
• Serber, Z., H. C. Lai, A. Yang, H. D. Ou, M. S. Sigal, A. E. Kelly, B. D. Darimont, P. H. Duijf, H. Van Bokhoven, F. McKeon, and V. Dotsch. 2002. A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol. Cell. Biol. 22:8601–8611.
   PubMed Web of Science ®Google Scholar
• Thanos, C. D., and J. U. Bowie. 1999. p53 family members p63 and p73 are SAM domain-containing proteins. Protein Sci. 8:1708–1710.
   PubMed Web of Science ®Google Scholar
• van Bokhoven, H., and H. G. Brunner. 2002. Splitting p63. Am. J. Hum. Genet. 71:1–13.
   PubMedGoogle Scholar
• van Bokhoven, H., and F. McKeon. 2002. Mutations in the p53 homolog p63: allele-specific developmental syndromes in humans. Trends Mol. Med. 8:133–139.
   PubMedGoogle Scholar
• von der Lehr, N., S. Johansson, S. Wu, F. Bahram, A. Castell, C. Cetinkaya, P. Hydbring, I. Weidung, K. Nakayama, K. I. Nakayama, O. Soderberg, T. K. Kerppola, and L. G. Larsson. 2003. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol. Cell 11:1189–1200.
   PubMed Web of Science ®Google Scholar
• Walker, D. R., J. P. Bond, R. E. Tarone, C. C. Harris, W. Makalowski, M. S. Boguski, and M. S. Greenblatt. 1999. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene 18:211–218.
   PubMedGoogle Scholar
• Wu, L., H. Zhu, L. Nie, and C. G. Maki. 2004. A link between p73 transcriptional activity and p73 degradation. Oncogene 23:4032–4036.
   PubMedGoogle Scholar
• Yang, A., M. Kaghad, D. Caput, and F. McKeon. 2002. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet. 18:90–95.
   PubMed Web of Science ®Google Scholar
• Yang, A., M. Kaghad, Y. Wang, E. Gillett, M. D. Fleming, V. Dotsch, N. C. Andrews, D. Caput, and F. McKeon. 1998. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2:305–316.
   PubMed Web of Science ®Google Scholar
• Zheng, H., H. You, X. Z. Zhou, S. A. Murray, T. Uchida, G. Wulf, L. Gu, X. Tang, K. P. Lu, and Z. X. Xiao. 2002. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 419:849–853.
   PubMed Web of Science ®Google Scholar